FDA's Center for Drug Evaluation and Research (CDER) approved its fourth novel agent of 2017, Valeant Pharmaceuticals International Inc.'s Siliq, in an otherwise quiet week for new product actions.
On the submission front, Mylan NV and Biocon Ltd. announced that their second 351(k) biologics license application (BLA), this one for a pegfilgrastim biosimilar
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?